IMNN - Imunon Inc
IEX Last Trade
1.14
0.050 4.386%
Share volume: 319,409
Last Updated: Fri 30 Aug 2024 09:59:45 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.09
0.05
4.59%
Fundamental analysis
27%
Profitability
24%
Dept financing
9%
Liquidity
68%
Performance
25%
Performance
5 Days
-8.73%
1 Month
-3.36%
3 Months
-21.23%
6 Months
17.35%
1 Year
-9.33%
2 Year
-48.66%
Key data
Stock price
$1.14
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.48 - $2.00
52 WEEK CHANGE
-$0.06
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Michael Tardugno
Region: US
Website: http://celsion.com/
Employees: 31
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://celsion.com/
Employees: 31
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.
Recent news